Evidence map›Paper›PMID 27463566›Full record

ReviewFuture medicinal chemistry2016

Targeting efflux pumps to overcome antifungal drug resistance.

Ann R Holmes, Tony S Cardno, J Jacob Strouse, Irena Ivnitski-Steele, Mikhail V Keniya, Kurt Lackovic, Brian C Monk, Larry A Sklar, Richard D Cannon

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Molecular mechanisms drivingFrontiers in molecular biosciences · 2026
    Review
  9. Functional characterization ofFrontiers in microbiology · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ann R HolmesSir John Walsh Research Institute, University of Otago Faculty of Dentistry, PO Box 647, Dunedin 9054, New Zealand.
Tony S CardnoDepartment of Biochemistry, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
J Jacob StrouseNew Mexico Center for Molecular Discovery, University of New Mexico, Albuquerque, New Mexico, USA.
Irena Ivnitski-SteeleNew Mexico Center for Molecular Discovery, University of New Mexico, Albuquerque, New Mexico, USA.
Mikhail V KeniyaSir John Walsh Research Institute, University of Otago Faculty of Dentistry, PO Box 647, Dunedin 9054, New Zealand.
Kurt LackovicWalter & Eliza Hall Institute of Medical Research Biotechnology Center, Melbourne, Australia.
Brian C MonkSir John Walsh Research Institute, University of Otago Faculty of Dentistry, PO Box 647, Dunedin 9054, New Zealand.
Larry A SklarNew Mexico Center for Molecular Discovery, University of New Mexico, Albuquerque, New Mexico, USA.
Richard D CannonSir John Walsh Research Institute, University of Otago Faculty of Dentistry, PO Box 647, Dunedin 9054, New Zealand.

Funding

Yeast Biology ConsortiumU54MH084690 · NIMH · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI SKLAR, LARRY A. · 2008 to 2013
$14.4M
New Mexico Molecular Libraries Screening Center(RMI)U54MH074425 · NIMH · UNIVERSITY OF NEW MEXICO · PI SKLAR, LARRY A. · 2005 to 2008
$10.0M
LPAR Control of Oral Fibroblast Regenerative ResponsesR15DE016855 · NIDCR · CREIGHTON UNIVERSITY · PI CERUTIS, D. ROSELYN ROSELYN · 2005 to 2005
$214k
Identification of broad-spectrum antifungal efflux pump inhibitorsR03MH087406 · NIMH · UNIVERSITY OF OTAGO · PI CANNON, RICHARD D · 2009 to 2009
$27k
NIDCR NIH HHS R15 DE016855NIMH NIH HHS R03 MH087406NIMH NIH HHS U54 MH074425NIMH NIH HHS U54 MH084690
6 · The paper itself

Abstract

Resistance to antifungal drugs is an increasingly significant clinical problem. The most common antifungal resistance encountered is efflux pump-mediated resistance of Candida species to azole drugs. One approach to overcome this resistance is to inhibit the pumps and chemosensitize resistant strains to azole drugs. Drug discovery targeting fungal efflux pumps could thus result in the development of azole-enhancing combination therapy. Heterologous expression of fungal efflux pumps in Saccharomyces cerevisiae provides a versatile system for screening for pump inhibitors. Fungal efflux pumps transport a range of xenobiotics including fluorescent compounds. This enables the use of fluorescence-based detection, as well as growth inhibition assays, in screens to discover compounds targeting efflux-mediated antifungal drug resistance. A variety of medium- and high-throughput screens have been used to identify a number of chemical entities that inhibit fungal efflux pumps.

Indexed as

Antifungal AgentsAzolesDrug Resistance, FungalFungiHumansMembrane Transport ProteinsMicrobial Sensitivity TestsMycosesAntifungal AgentsAzolesMembrane Transport ProteinsABC and MFS transportersantifungal drug resistanceazolechemosensitizationheterologous expressionhigh-throughput screen

Identifiers

PMID27463566
PMCPMC5827819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.